Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma
Authors
Keywords
Bladder cancer, Immunotherapy, Guidelines, Consensus statement
Journal
Journal for ImmunoTherapy of Cancer
Volume 5, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-08-11
DOI
10.1186/s40425-017-0271-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
- (2017) Andrea B. Apolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis
- (2017) Jiaying Wu et al. Scientific Reports
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin
- (2016) Ashish M. Kamat et al. EUROPEAN UROLOGY
- Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa–pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?
- (2016) Richard J. Sylvester et al. EUROPEAN UROLOGY
- Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non–Muscle-invasive Bladder Cancer
- (2016) Tom J.H. Arends et al. EUROPEAN UROLOGY
- Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.
- (2016) Arjun Vasant Balar et al. JOURNAL OF CLINICAL ONCOLOGY
- IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).
- (2016) Jean H. Hoffman-Censits et al. JOURNAL OF CLINICAL ONCOLOGY
- Definitions, End Points, and Clinical Trial Designs for Non–Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group
- (2016) Ashish M. Kamat et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
- (2016) Christophe Massard et al. JOURNAL OF CLINICAL ONCOLOGY
- Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes
- (2016) Christine Gan et al. JOURNAL OF UROLOGY
- Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline
- (2016) Sam S. Chang et al. JOURNAL OF UROLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
- (2016) Padmanee Sharma et al. LANCET ONCOLOGY
- Combination of Intravesical Chemotherapy and Bacillus Calmette–Guerin Versus Bacillus Calmette–Guerin Monotherapy in Intermediate- and High-risk Nonmuscle Invasive Bladder Cancer
- (2016) Jianfeng Cui et al. MEDICINE
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts
- (2016) Sonja Althammer et al. Journal for ImmunoTherapy of Cancer
- Immune Therapies in Non-Muscle Invasive Bladder Cancer
- (2015) Philip L. Ho et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non–muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013
- (2015) Luis Martínez-Piñeiro et al. EUROPEAN UROLOGY
- Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer
- (2015) Ashish M. Kamat et al. Nature Reviews Urology
- Impact of Patient Navigation on Timely Cancer Care: The Patient Navigation Research Program
- (2014) Karen M. Freund et al. JNCI-Journal of the National Cancer Institute
- Defining and Treating the Spectrum of Intermediate Risk Nonmuscle Invasive Bladder Cancer
- (2014) Ashish M. Kamat et al. JOURNAL OF UROLOGY
- The mechanism of action of BCG therapy for bladder cancer—a current perspective
- (2014) Gil Redelman-Sidi et al. Nature Reviews Urology
- Risk Prediction Scores for Recurrence and Progression of Non-Muscle Invasive Bladder Cancer: An International Validation in Primary Tumours
- (2014) Moniek M. Vedder et al. PLoS One
- Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS)
- (2013) J. Alfred Witjes et al. BJU INTERNATIONAL
- Intravesical bacille Calmette-Guérin (BCG) in immunologically compromised patients with bladder cancer
- (2013) Harry W. Herr et al. BJU INTERNATIONAL
- Comparison of expected treatment outcomes, obtained using risk models and international guidelines, with observed treatment outcomes in a Dutch cohort of patients with non-muscle-invasive bladder cancer treated with intravesical chemotherapy
- (2013) Rianne J.M. Lammers et al. BJU INTERNATIONAL
- Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer
- (2013) Matthew D. Galsky et al. CANCER
- EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
- (2013) Marko Babjuk et al. EUROPEAN UROLOGY
- Nurse Navigators in Early Cancer Care: A Randomized, Controlled Trial
- (2013) Edward H. Wagner et al. JOURNAL OF CLINICAL ONCOLOGY
- Muscle Invasive Bladder Cancer: Examining Survivor Burden and Unmet Needs
- (2013) Nihal E. Mohamed et al. JOURNAL OF UROLOGY
- The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma
- (2013) Howard L. Kaufman et al. Nature Reviews Clinical Oncology
- Strategies for Optimizing Bacillus Calmette-Guérin
- (2013) Jay B. Shah et al. UROLOGIC CLINICS OF NORTH AMERICA
- Interferon alfa in the treatment paradigm for non–muscle-invasive bladder cancer
- (2013) Donald Lamm et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- The Origin, Evolution, and Principles of Patient Navigation
- (2012) H. P. Freeman CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- ICUD-EAU International Consultation on Bladder Cancer 2012: Non–Muscle-Invasive Urothelial Carcinoma of the Bladder
- (2012) Maximilian Burger et al. EUROPEAN UROLOGY
- Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance
- (2012) Jorg Oddens et al. EUROPEAN UROLOGY
- Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette–Guérin instillation therapy of patients with carcinoma in situ of the bladder: A subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up
- (2012) Riikka Järvinen et al. SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY
- Compliance with guidelines for patients with bladder cancer
- (2011) Karim Chamie et al. CANCER
- The Future of Drug Development in Urothelial Cancer
- (2011) Robert Dreicer JOURNAL OF CLINICAL ONCOLOGY
- Factors Affecting Response to Bacillus Calmette-Guérin Plus Interferon for Urothelial Carcinoma in Situ
- (2011) Henry M. Rosevear et al. JOURNAL OF UROLOGY
- A Review of Current Guidelines and Best Practice Recommendations for the Management of Nonmuscle Invasive Bladder Cancer by the International Bladder Cancer Group
- (2011) Maurizio Brausi et al. JOURNAL OF UROLOGY
- Intravesical Bacillus Calmette-Guérin Outcomes in Patients With Bladder Cancer and Asymptomatic Bacteriuria
- (2011) Harry W. Herr JOURNAL OF UROLOGY
- Recognition and Treatment of BCG Failure in Bladder Cancer
- (2011) Andrew J. Lightfoot et al. TheScientificWorldJOURNAL
- Sequential Intravesical Chemoimmunotherapy with Mitomycin C and Bacillus Calmette-Guérin and with Bacillus Calmette-Guérin Alone in Patients with Carcinoma in Situ of the Urinary Bladder: Results of an EORTC Genito-Urinary Group Randomized Phase 2 Trial (30993)
- (2010) Willem Oosterlinck et al. EUROPEAN UROLOGY
- Use of Radical Cystectomy for Patients With Invasive Bladder Cancer
- (2010) J. L. Gore et al. JNCI-Journal of the National Cancer Institute
- Bacillus Calmette-Guérin With or Without Interferon α-2b and Megadose Versus Recommended Daily Allowance Vitamins During Induction and Maintenance Intravesical Treatment of Nonmuscle Invasive Bladder Cancer
- (2010) Kenneth G. Nepple et al. JOURNAL OF UROLOGY
- Safety and Efficacy of Intravesical Bacillus Calmette-Guérin Plus Interferon α-2b Therapy for Nonmuscle Invasive Bladder Cancer in Patients With Prosthetic Devices
- (2010) Henry M. Rosevear et al. JOURNAL OF UROLOGY
- Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Guérin-induced toxicity?
- (2009) Rocco Damiano et al. BJU INTERNATIONAL
- Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder
- (2009) Richard J. Sylvester et al. EUROPEAN UROLOGY
- Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model
- (2009) Jesus Fernandez-Gomez et al. JOURNAL OF UROLOGY
- Clinical Practice Recommendations for the Management of Non–Muscle Invasive Bladder Cancer
- (2008) Donald Lamm et al. EUROPEAN UROLOGY SUPPLEMENTS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More